All times are shown in CEST

8:50 am Chair’s Opening Remarks

9:00 am Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression


  • Nouscom Cancer vaccines targeting neoantigens:
  • Rely on effective neoantigens prediction methods
  • Can encode a large number of neoantigens
  • Induce a robust neoantigens’ specific CD4 and CD8 T cell immunity
  • Cure large established tumours in mice when combined with checkpoint blockade

9:30 am Panel Discussion: Evaluating Combination Therapies


  • The hasty evolvement of combination strategies
  • Combinational therapies employing both neoantigen-based approaches and immune checkpoint blockade (ICB) are underway to overcome ICB-induced immune resistance and maximize antitumor immune activity
  • Investigating the safety and efficacy of neoantigen vaccine therapy plus chemotherapy in adjuvant setting
  • Discuss regulatory pathway and limitations to approve two new drugs
  • How to identify a clear biologic effect caused by combination
  • Improving Clinical Efficacy through Immunotherapy Combinations

10:00 am Extrapolation of epitope prediction from IO onto infectious diseases (lessons learned)


  • Differences and synergies between personalized/shared neoantigen identification, and target prediction for infectious diseases
  • Exploration of different IO epitope prediction tools and their extrapolation capabilities for general infectious diseases
  • Use case: designing an optimal construct for intranasal RNA-based SARS-CoV2 vaccine

10:30 am Targeting antigens to antigen presenting cells induce effective anti-tumor efficacy as monotherapy and as combination therapy


  • Vaccibody’s 3 modular format optimized for induction of rapid, strong and broad immune responses
  • Tailoring the immune response profile by targeting different receptors on antigen presenting cells
  • Combinations and applicability within personalized and off-the shelf cancer vaccines and beyond

11:00 am Morning Refreshments & Networking


Examining Binding Affinity of Neo-epitopes to Determine Cancer Vaccination Strategies

11:30 am High-affinity Neoepitope-Specific T Cells Accumulate in Tumours

  • Alexandre Harari Group leader, Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne

12:00 pm Characterizing Epitopes for Cancer Vaccines and T Cell Therapeutics

Identifying Novel Targets to Drive Development of Next Generation Cancer Vaccines

12:30 pm Are Immunogenic Tumours the Best Targets of Tumour Vaccination?


  • Identifying the best targets for tumour vaccination
  • Tumour infiltration and PDL1expression to identify the tumours that are more sensitive to vaccines
  • Assessing non immunogenic tumours
  • Outlining considerations for the future of neoantigens


Addressing the Importance of Clinical Trial Design and Optimizing Lead Time to Accelerate Development of Neoantigen Therapies

11:30 am Designing the Right Clinical Trial for a Neoantigen Platform

  • Russell Pachynski Assistant Professor, Division of Oncology, Washington University School of Medicine


  • Evaluation of options for clinical trial design
  • How to define better clinical endpoints
  • Considerations for in-house development and manufacturing vs outsourcing

12:00 pm Entering clinical trials with a personalized oral bacteria-based DNA vaccine – Overcoming hurdles and challenges


  • Selecting the neoantigen prediction technology
  • Optimizing the manufacturing process to minimize the time to administration
  • Ensuring compliance with regulatory requirements
  • Designing the clinical study

Overcoming the Technical Challenges of Personalised Therapy to Allow For Seamless Therapeutic Delivery

12:30 pm Key Considerations & Strategies for Technical Development of Personalised Neoantigen-based Cancer Vaccine and T-Cell Therapy

  • Pranay Khare Director, Cell Therapy Development & Manufacturing, Genocea Biosciences


  • Considerations for process design and specifications for a personalized neoantigen based vaccine and a personalized neoantigen based cell therapy.
  • Approaches for dealing with human to human variability as well as process variability.
  • Key supply chain considerations for ensuring supply of personalized product to the early phase clinical trials

13:00 pm Lunch

2:00 pm TG4050 : Viral immunotherapy meets AI technology


  • TG4050 is based on a decade long expertise in designing viral vectors
  • Viral immunotherapy constitutes a promising modality harnessing the natural sensitivity of immune system to virus to target cancer cells
  • Viruses can be modified to alter their immunogenic properties and enhance anti-tumor activity
  • A review of how different viruses can be combined to enhance immunogenicity and optimize lead time

2:30 pm The Impact of Stimulatory and Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical and Pre- Clinical Results

  • Hubert Lam Director, Pre-clinical Development, Genocea


  • ATLAS identifies stimulatory and inhibitory CD4+ and CD8+ T cell responses to neoantigens and common antigens
  • Preclinical models show the deleterious impact of inhibitory T cell responses on anti-tumor immunity
  • Be careful, common neoantigens may differ from common mutations
  • The GEN-009 immunotherapy, designed with personalized ATLAS-identified stimulatory neoantigens has resulted in unprecedented breadth of immune response in the ongoing GEN-009 101 Phase 1/2a clinical trial

3:00 pm Multi-step Screening of Neoantigens’ HLA- and TCR-interfaces Improves Prediction of Survival in Urothelial Bladder Cancer

3:30 pm Journey to CAR T-cell Therapy


• Emily Whitehead’s journey to become the first pediatric cancer patient to receive CAR T-cell therapy
• Establishing the Emily Whitehead Foundation to raise research funding and help more kids like Emily receive
less toxic therapies
• A present day update on the Whitehead family, including news about their new book “Praying For Emily”

4:00 pm Chairs Closing Remarks

4:15 pm End of Day 2 & Close of Neoantigen Summit